文献速递先天性心脏病外科

开窗通畅性对Fontan长期结局的影响

Impact of Fenestration Patency on Long-Term Fontan Outcomes.
PubMed 文献 · Eur J Cardiothorac Surg · 2026-01-01

本研究评估Fontan术后1年开窗通畅性对长期结局的影响,纳入112例行开窗全腔静脉肺动脉连接术患者中的105例,按1年时开窗状态分为通畅组(43例)和闭合组(62例)。结果显示开窗通畅组术后1年体循环心室舒张末期压力较高,但蛋白丢失性肠病发生率显著低于闭合组,而Fontan相关肝病累积发生率无差异。结论认为常规开窗策略可能改善长期结局。

要点

  • 开窗通畅组1年时体循环心室舒张末期压力较高。
  • 开窗闭合组蛋白丢失性肠病发生率显著更高。
  • 两组Fontan相关肝病累积发生率无显著差异。

核心结论

  • 开窗通畅虽与术后1年体循环心室舒张末期压力升高相关,但可能改善包括蛋白丢失性肠病在内的长期结局。
  • 由于术前难以预测开窗最终是否通畅,常规开窗策略似乎是合理的。

研究设计与样本

  • 多中心回顾性研究,4家机构共112例开窗全腔静脉肺动脉连接术患者,分析其中105例有1年导管检查且随访≥3年者。
  • 按1年时开窗状态分为通畅组(Group F,n=43)和闭合组(Group C,n=62)。

主要发现

  • Fontan中位年龄23个月(IQR 15-33),术前血流动力学两组无差异。
  • 术后1年体循环心室舒张末期压力通畅组高于闭合组(F:8 [5-9] vs C:6 [5-8] mmHg,P = .007)。
  • 蛋白丢失性肠病闭合组显著更常见(F:5.0% vs C:27.0%,P = .038)。
  • Fontan相关肝病累积发生率两组无显著差异(F:12.5% vs C:9.7%,P = .69)。

临床怎么用

  • Fontan完成时常规开窗以稳定早期循环。
  • 术后1年开窗通畅者需关注体循环心室舒张末期压力升高。
  • 开窗闭合者应警惕蛋白丢失性肠病发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Routine creation of a fenestration during Fontan completion is our policy to stabilize early circulation. This study evaluated its validity by examining the impact of fenestration patency at 1 year on long-term outcomes. METHODS: Among 112 patients who underwent fenestrated total cavopulmonary connection at 4 institutions, 105 with 1-year catheterization and ≥3 years of follow-up were analysed. Patients were classified by fenestration status at 1 year: patent (Group F, n = 43) and closed (Group C, n = 62). Preoperative and 1-year catheter data and long-term complications-Fontan-associated liver disease (FALD), protein-losing enteropathy (PLE), and catheter interventions excluding veno-venous collaterals-were compared. RESULTS: The median age at Fontan was 23 months (interquartile range [IQR]: 15-33). Preoperative haemodynamics showed no differences between the groups. At postoperative 1 year, systemic ventricular end-diastolic pressure (SVEDP) was higher in Group F (F: 8 [5-9] vs C: 6 [5-8] mmHg, P = .007). Protein-losing enteropathy was significantly more common in the Group C (F: 5.0% vs C: 27.0%, P = .038). In contrast, there was no significant difference in the cumulative incidence of FALD between the 2 groups (F: 12.5% vs C: 9.7%, P = .69). CONCLUSIONS: Although patent fenestration was associated with an increased SVEDP at 1 year postoperatively, it may improve long-term outcomes including PLE. As predicting eventual fenestration patency from preoperative data is difficult, our policy of routine fenestration creation appears to be a valid strategy. CLINICAL REGISTRATION NUMBER: Kitasato University, No. B23-130; February 7, 2024.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Horie S, Shikata F, Oka N, et al. Impact of Fenestration Patency on Long-Term Fontan Outcomes. Eur J Cardiothorac Surg. 2026. PMID: 41557473. doi:10.1093/ejcts/ezag047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。